Lung Disease - Xconomy

by in

Entry	Author	Date	Location
Genoa Pharma Aims To Satisfy Big Pharma’s Hunger for IPF Drugs	Luke Timmerman	03/30/12	San Diego
Pulmatrix Snags $14M, Embera Adds for $4.5 Addiction Drugs, Daktari Gets $1.2M, & More Boston-Area Life Sciences News	Erin Kutz	08/19/11	Boston
Bristol-Myers Acquires Amira Pharmaceuticals for $325 Million, Scoops Up Lung Drug	Luke Timmerman	07/21/11	San Diego
InterMune Wins EU Approval	Luke Timmerman	03/03/11	San Francisco
Pearl Hires New CEO	Luke Timmerman	02/24/11	San Francisco
Stromedix Chief, After Reloading the Company Treasury, Sets Sight on Trial for Deadly Lung Disease	Ryan McBride	02/07/11	Boston
PneumRx Raises $33M	Wade Roush	01/04/11	San Francisco
Intermune Gets EU Advisory Nod; Shares Boom	Luke Timmerman	12/17/10	San Francisco
Montgomery Joins Alder Board	Luke Timmerman	11/01/10	Seattle
Spiration Borrows $6.5M	Luke Timmerman	04/28/10	Seattle
Uptake Medical Nabs $3.4M	Luke Timmerman	09/11/09	Seattle
Visible Raises $6M, Vulcan Goes Deep with BiPar, IdeaScale Serves White House, & More Seattle-Area Deals News	Gregory T. Huang	05/26/09	Seattle
CMC Icos to Make Lung Drug	Luke Timmerman	05/11/09	Seattle
$2.6M Helps Healionics Heal, Uptake Takes In $3M, BlueKai Gets $10.5M Boost, & More Seattle-Area Deals News	Gregory T. Huang	12/16/08	Seattle
Aires Pharmaceuticals Emerges from Stealth Mode With Drug for Pulmonary Arterial Hypertension	Luke Timmerman	11/05/08	San Diego
Page 1 of 1

Xconomy National